Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $20.63
Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus recommendation of “Buy” from the eleven research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $23.50.
A number of research analysts have commented on the company. Zacks Investment Research cut NeoGenomics from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Benchmark set a $27.00 price target on NeoGenomics and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Leerink Swann set a $30.00 price target on NeoGenomics and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Needham & Company LLC set a $27.00 price target on NeoGenomics and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, Raymond James upped their price target on NeoGenomics from $23.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 31st.
In other news, Director Raymond R. Hipp sold 150,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $22.41, for a total transaction of $3,361,500.00. Following the sale, the director now owns 256,059 shares of the company’s stock, valued at $5,738,282.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.80% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of NEO. NEXT Financial Group Inc increased its holdings in NeoGenomics by 200.0% in the second quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock valued at $59,000 after buying an additional 1,800 shares during the last quarter. Winslow Evans & Crocker Inc. purchased a new position in shares of NeoGenomics during the second quarter worth about $92,000. Amundi Pioneer Asset Management Inc. purchased a new position in shares of NeoGenomics during the fourth quarter worth about $103,000. Great West Life Assurance Co. Can grew its holdings in shares of NeoGenomics by 53.9% during the fourth quarter. Great West Life Assurance Co. Can now owns 9,851 shares of the medical research company’s stock worth $120,000 after purchasing an additional 3,451 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund acquired a new stake in shares of NeoGenomics during the first quarter worth about $132,000. 84.07% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:NEO traded up $1.14 during trading hours on Tuesday, hitting $24.75. 888,732 shares of the stock were exchanged, compared to its average volume of 1,090,783. NeoGenomics has a 52-week low of $11.05 and a 52-week high of $26.14. The business’s fifty day simple moving average is $23.27. The company has a current ratio of 4.67, a quick ratio of 4.52 and a debt-to-equity ratio of 0.25. The firm has a market cap of $2.36 billion, a P/E ratio of 190.38 and a beta of 0.96.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. NeoGenomics had a return on equity of 4.97% and a net margin of 0.57%. The firm had revenue of $101.71 million for the quarter, compared to analysts’ expectations of $97.32 million. During the same period in the prior year, the firm posted $0.05 earnings per share. The firm’s quarterly revenue was up 50.1% on a year-over-year basis. As a group, sell-side analysts expect that NeoGenomics will post 0.18 earnings per share for the current fiscal year.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: Cost of Equity For A Business, Investors
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source